{"id":"menin","name":"Menin","symbol":"MEN1","route":"/targets/menin/","asOf":"2026-09-04","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7010","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000133895","uniprot":"https://www.uniprot.org/uniprotkb/O00255/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/O00255","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL1615381","open-targets":"https://platform.opentargets.org/target/ENSG00000133895","civic":"https://civicdb.org/genes/4221/summary","oncokb":"https://www.oncokb.org/gene/MEN1","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=MEN1","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=MEN1","depmap":"https://depmap.org/portal/gene/MEN1?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000133895-MEN1","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/4221","omim":"https://www.omim.org/entry/613733"}],"products":[{"id":"revumenib","name":"Revumenib","status":"approved","modality":"Small-molecule menin inhibitor","route":"/drugs/revumenib/"},{"id":"ziftomenib","name":"Ziftomenib","status":"approved","modality":"Small-molecule menin inhibitor","route":"/drugs/ziftomenib/"}],"trials":[{"id":"nct07007312","name":"Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML","nct":"NCT07007312","phase":"3","status":"recruiting"},{"id":"nct07211958","name":"Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation","nct":"NCT07211958","phase":"3","status":"recruiting"},{"id":"myelomatch","name":"myeloMATCH","nct":"NCT05564390","phase":"platform","status":"recruiting"},{"id":"nct07623616","name":"A Phase 2 Clinical Study of Ziftomenib in Patients With Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia","nct":"NCT07623616","phase":"2","status":"recruiting"},{"id":"komet-001","name":"KOMET-001","nct":"NCT04067336","phase":"1/2","status":"positive"},{"id":"augment-101","name":"AUGMENT-101","nct":"NCT04065399","phase":"1/2","status":"positive"}],"pathways":["epigenetic-reprogramming","menin-kmt2a","transcription-addiction"],"companies":["kura-oncology","syndax"],"keyPapers":["paper-augment-101-revumenib-menin-nature-2023"],"hotspots":[],"openQuestions":[{"id":"menin-frontline","question":"Do menin inhibitors added to induction chemotherapy or venetoclax-azacitidine improve survival in newly diagnosed NPM1-mutant and KMT2A-rearranged AML?","stage":"clinical","actor":"industry","source":{"label":"AUGMENT-101 (ClinicalTrials.gov)","url":"https://clinicaltrials.gov/study/NCT04065399"}}],"assays":[],"resistance":[],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}